Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.81 |
| ▸ | POLB | P06746 | 5/20 | 0.81 |
| ▸ | TP53 | P04637 | 7/20 | 0.78 |
| ▸ | TSHR | P16473 | 3/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1893639 | 0.97 | MAPT (0.79) | MAPTPOLBTP53TSHRGAA | |
| SCHEMBL1057420 | 0.88 | MAPT (0.62) | MAPTPOLBTP53TSHRGAA | |
| SCHEMBL1057419 | 0.85 | MAPT (0.58) | MAPTPOLBTP53TSHRGAA | |
| SCHEMBL1007557 | 0.85 | MAPT (0.73) | MAPTPOLBTP53TSHRGAA | |
| SCHEMBL1892539 | 0.83 | MAPT (0.56) | MAPTPOLBTP53TSHRGAA | |
| SCHEMBL1007661 | 0.82 | MAPT (0.69) | MAPTPOLBTP53TSHRGAA | |
| SCHEMBL1008062 | 0.81 | MAPT (0.79) | MAPTPOLBTP53SMN1; SMN2LMNA | |
| SCHEMBL1007604 | 0.81 | MAPT (0.56) | MAPTPOLBTP53TSHRGAA | |
| SCHEMBL1009356 | 0.80 | SMN1; SMN2 (0.62) | MAPTPOLBTP53TSHRGAA | |
| SCHEMBL1006822 | 0.80 | POLB (0.63) | MAPTPOLBTP53TSHRGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118236-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-19 | — | — | US | disclosed |
| US-20110118236-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-19 | — | — | US | disclosed |
| EP-2269990-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2011-01-05 | — | — | EP | disclosed |
| EP-2269990-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2011-01-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118236-A1 | HETEROCYCLIC COMPOUND | GRIN1, GRM1, GRIK1 | MAPT 4623/4885POLB 3571/4885TP53 3973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.